Ming-Hui Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8728656/publications.pdf

Version: 2024-02-01

777949 889612 40 550 13 19 citations h-index g-index papers 49 49 49 659 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virologica Sinica, 2022, 37, 390-397.	1.2	10
2	Hepatitis B coreâ€related antigen serum levels are associated with significant liver fibrosis in treatmentâ€naive chronic HBV infection patients. Journal of Viral Hepatitis, 2022, 29, 438-446.	1.0	1
3	Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients. Frontiers in Immunology, 2022, 13, .	2.2	10
4	Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report. Infectious Agents and Cancer, 2022, 17, .	1.2	4
5	Pathway of Cell Death and Its Role in Virus Infection. Viral Immunology, 2022, 35, 444-456.	0.6	4
6	Impact of in vitro <scp>fertilizationâ€embryo</scp> transfer on <scp>motherâ€toâ€infant</scp> transmission in women with chronic <scp>HBV</scp> infection. Liver International, 2022, 42, 2167-2174.	1.9	1
7	Developmental Consequences of Prenatal Telbivudine Exposure during the Third Trimester. Clinical Gastroenterology and Hepatology, 2021, 19, 1061-1063.	2.4	2
8	Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonl±-2a. Virologica Sinica, 2021, 36, 311-320.	1.2	17
9	Screening varices in patients with HBVâ€related cirrhosis on antiviral therapy: Platelet alone or together with LSM. Liver International, 2021, 41, 369-377.	1.9	4
10	Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up. Virulence, 2021, 12, 1527-1537.	1.8	2
11	The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. BioMed Research International, 2021, 2021, 1-14.	0.9	11
12	Secondary hemophagocytic lymphohistiocytosis characterized by liver injury. Medicina ClÃnica, 2021, 157, 548-549.	0.3	0
13	Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver International, 2021, 41, 1498-1508.	1.9	24
14	Transforming growth factor \hat{l}^2 as a possible independent factor in chronic hepatitis B. Archives of Virology, 2021, 166, 1853-1858.	0.9	4
15	HBeAg-positive patients with HBsAg  < 100ÂlU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. Journal of Gastroenterology, 2021, 56, 856-867.	2.3	18
16	Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy. Biosafety and Health, 2021, 3, 190-196.	1.2	0
17	Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report. Viral Immunology, 2021, , .	0.6	5
18	Application of Lab-on-Chip for Detection of Microbial Nucleic Acid in Food and Environment. Frontiers in Microbiology, 2021, 12, 765375.	1.5	5

#	Article	IF	CITATIONS
19	Advances in Metagenomics and Its Application in Environmental Microorganisms. Frontiers in Microbiology, 2021, 12, 766364.	1.5	54
20	Association of cytokines with hepatitis B virus and its antigen. Journal of Medical Virology, 2020, 92, 3426-3435.	2.5	12
21	The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients. BMC Infectious Diseases, 2020, 20, 590.	1.3	4
22	Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Military Medical Research, 2020, 7, 28.	1.9	58
23	Field applicable detection of hepatitis B virus using internal controlled duplex recombinaseâ€aided amplification assay and lateral flow dipstick assay. Journal of Medical Virology, 2020, 92, 3344-3353.	2.5	17
24	Comparison of third-generation sequencing approaches to identify viral pathogens under public health emergency conditions. Virus Genes, 2020, 56, 288-297.	0.7	17
25	The association between frailty and incidence of dementia in Beijing: findings from 10/66 dementia research group population-based cohort study. BMC Geriatrics, 2020, 20, 138.	1.1	20
26	Predictors of sustained functional cure in hepatitis B envelope antigenâ€negative patients achieving hepatitis B surface antigen seroclearance with interferonâ€alpha–based therapy. Journal of Viral Hepatitis, 2019, 26, 32-41.	1.0	27
27	Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigenâ€negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. Journal of Viral Hepatitis, 2019, 26, 42-49.	1.0	17
28	Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clinical and Experimental Medicine, 2019, 19, 309-320.	1.9	12
29	Applicability of duplex real time and lateral flow strip reverse-transcription recombinase aided amplification assays for the detection of Enterovirus 71 and Coxsackievirus A16. Virology Journal, 2019, 16, 166.	1.4	14
30	The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. American Journal of Gastroenterology, 2018, 113, 686-693.	0.2	32
31	Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B. Chinese Medical Journal, 2018, 131, 1813-1818.	0.9	14
32	Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection. Chinese Medical Journal, 2018, 131, 43-49.	0.9	10
33	Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy. Journal of Interferon and Cytokine Research, 2018, 38, 197-205.	0.5	14
34	Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 470-479.	0.6	9
35	Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Chinese Medical Journal, 2017, 130, 559-565.	0.9	21
36	Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-na \tilde{A} ve Patients with Chronic Hepatitis B Virus Infection. Chinese Medical Journal, 2017, 130, 2697-2702.	0.9	11

Ming-Hui Li

#	Article	IF	CITATION
37	Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B. Chinese Medical Journal, 2017, 130, 1810-1815.	0.9	11
38	Plasma NT-proBNP is independently associated with albuminuria in type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 669-674.	1.2	5
39	Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World Journal of Hepatology, 2016, 8, 637.	0.8	22
40	Therapeutic Effects of NK-HDAC-1, a Novel Histone Deacetylase Inhibitor, on Collagen-Induced Arthritis Through the Induction of Apoptosis of Fibroblast-Like Synoviocytes. Inflammation, 2013, 36, 888-896.	1.7	20